Jade Biosciences Inc [JBIO] stock is trading at $9.04, down -1.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JBIO shares have gain 4.75% over the last week, with a monthly amount glided 20.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jade Biosciences Inc [NASDAQ: JBIO] stock has seen the most recent analyst activity on July 14, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $16. Previously, Guggenheim upgraded its rating to Buy on June 16, 2025, and kept the price target unchanged to $14. On May 07, 2025, Wedbush initiated with a Outperform rating and assigned a price target of $17 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $19 on May 05, 2025. TD Cowen initiated its recommendation with a Buy and recommended $10 as its price target on May 02, 2025. Wells Fargo downgraded its rating to Equal Weight for this stock on June 18, 2024, and downed its price target to $2. In a note dated June 18, 2024, TD Cowen downgraded an Hold rating on this stock.
Jade Biosciences Inc [JBIO] stock has fluctuated between $6.57 and $13.50 over the past year. Currently, Wall Street analysts expect the stock to reach $16.5 within the next 12 months. Jade Biosciences Inc [NASDAQ: JBIO] shares were valued at $9.04 at the most recent close of the market. An investor can expect a potential return of 82.52% based on the average JBIO price forecast.
Analyzing the JBIO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.53 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.58 points at the first support level, and at 8.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.44, and for the 2nd resistance point, it is at 9.84.
Ratios To Look Out For
For context, Jade Biosciences Inc’s Current Ratio is 10.31. As well, the Quick Ratio is 10.31, while the Cash Ratio is 10.22.
Transactions by insiders
Recent insider trading involved Atlas Venture Fund XII, L.P., Shareholder, that happened on Jun 25 ’25 when 28977.0 shares were purchased. Shareholder, Atlas Venture Associates XII, completed a deal on Jun 25 ’25 to buy 235.0 shares. Meanwhile, Shareholder Atlas Venture Fund XII, L.P. bought 16132.0 shares on Jun 24 ’25.
